Risankizumab & Apremilast Come to Market in Canada
Phase 3 Results for Olokizumab in RA Patients
Low-Dose Methotrexate Can Cause Adverse Effects
Risankizumab Demonstrates Superiority to Secukinumab for Plaque Psoriasis
Phase 3 Results for Ixekizumab Promising in Patients with Non-Radiographic Axial Spondyloarthritis
Anifrolumab Promising for SLE
Tildrakizumab Promising for Psoriasis in Patients with PsA
Rituximab-abbs Available in the U.S.; Plus Upadacitinib in Phase 3 Trials for PsA
Scottish Medicines Consortium Recommends Risankizumab; Plus Real-World Data on Secukinumab
- 1
- 2
- 3
- …
- 18
- Next Page »